Apellis Pharmaceuticals

General Information

We are a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control a broad array of complement-dependent autoimmune and inflammatory diseases.  

Employees: 28
Founded: 2009
Contact Information
Address 6400 Westwind Way, Suite A, Crestwood, KY 40014, US
Phone Number (502) 241-4114
Web Address http://www.apellis.com
View Prospectus: Apellis Pharmaceuticals
Financial Information
Market Cap $689.6mil
Revenues $0 mil (last 12 months)
Net Income $-35.0 mil (last 12 months)
IPO Profile
Symbol APLS
Exchange NASDAQ
Shares (millions): 10.7
Price range $14.00 - $14.00
Est. $ Volume $150.0 mil
Manager / Joint Managers Citigroup/ J.P. Morgan/ Evercore ISI
CO-Managers -
Expected To Trade: 11/9/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change